The planned Phase 1 clinical trial includes patients with tumor types with a high frequency of Hippo pathway alterations, including NF2-deficient malignant mesothelioma and some soft tissue sarcomas with YAP/TAZ genetic fusions, including Epithelioid Hemangioendothelioma (EHE), a rare form of soft tissue sarcoma that has a significant unmet medical need with no currently approved therapy for advanced or metastatic disease. As supported by preclinical work, Ikena also plans to explore combinations of IK-930 with other targeted agents for the treatment of solid tumors, such as EGFR-mutant non-small cell lung cancer (NSCLC) and KRAS-mutant solid tumors.
Archives for January 2022
Together, the US, UK, and Australia EHE foundations team up to strengthen the force against EHE. This group provides a quarterly update, which is led by the UK and includes research news, patient and fundraising stories, and much more! Click here to view the most recent edition of our online EHE newsletter, The Pledge.